Pharma BD Deal Intelligence
Shire paid $5.2B for NPS Pharmaceuticals to acquire Natpara and Gattex/Revestive for rare gastrointestinal conditions with few alternatives. The deal expanded Shire's rare disease portfolio beyond hematology and immunology, adding durable orphan franchises that carried into the Takeda era.
Shire announced acquisition of NPS Pharmaceuticals for $46 per share in cash, approximately $5.2 billion, to build a leading biotech through rare disease…
Shire announced its $5.2 billion acquisition of NPS Pharmaceuticals to strengthen its rare disease leadership, gaining key products Gattex and Natpara for GI…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Shire acquired NPS Pharmaceuticals for $5.2B for rare gastrointestinal diseases.
15K US cases/yr · $800M Global SBS Market (2015)
Short bowel syndrome is a rare malabsorption disorder where patients lack sufficient functional intestine. NPS's Gattex (teduglutide) was the first GLP-2 analog approved for SBS, offering an alternative to lifelong parenteral nutrition.
Gattex was the only approved GLP-2 analog for SBS at deal time. The rare GI space had limited competition, with parenteral nutrition as the standard of care. Shire sought NPS to build its rare disease GI franchise alongside Natpara.
For rare GI diseases, gaining Gattex/Revestive and Natpara. Part of Shire PLC's $5.2B deal to acquire NPS Pharmaceuticals.
Shire PLC completed its acquisition of NPS Pharmaceuticals for $5.2B. Shire acquired NPS Pharmaceuticals for $5.2B for rare gastrointestinal diseases.
Natpara for chronic hypoparathyroidism; added $24M in first partial year. Regulatory step in Shire PLC's acquisition process for NPS Pharmaceuticals.
NPS assets became part of Takeda rare disease franchise. Part of Shire PLC's $5.2B deal to acquire NPS Pharmaceuticals.
See timeline for full assessment. Assessment of Shire PLC's $5.2B acquisition of NPS Pharmaceuticals and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / NPS Pharmaceuticals (this deal) | 2015 | $5.2B | 78 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2015 deals · Shire plc deals · Rare Disease deals